| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.38▼ | 2.35▲ | 2.34▲ | 2.34▲ | 2.28▲ |
| MA10 | 2.37▼ | 2.34▲ | 2.32▲ | 2.29▲ | 2.02▲ |
| MA20 | 2.36▲ | 2.32▲ | 2.33▲ | 2.35▲ | 1.76▲ |
| MA50 | 2.33▲ | 2.32▲ | 2.32▲ | 2.05▲ | 2.00▲ |
| MA100 | 2.31▲ | 2.31▲ | 2.27▲ | 1.77▲ | 1.63▲ |
| MA200 | 2.32▲ | 2.27▲ | 2.29▲ | 2.04▲ | 1.54▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | 0.008▲ | 0.006▲ | -0.017▼ | 0.092▲ |
| RSI | 61.402▲ | 61.484▲ | 57.540▲ | 54.824▲ | 59.957▲ |
| STOCH | 79.861 | 88.633▲ | 87.743▲ | 79.602 | 73.301 |
| WILL %R | -41.667 | -16.129▲ | -16.129▲ | -18.947▲ | -23.207▲ |
| CCI | 57.143 | 176.879▲ | 189.329▲ | 36.009 | 103.294▲ |
|
Thursday, October 30, 2025 05:00 PM
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or "the Company") ...
|
|
Friday, October 17, 2025 08:23 AM
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.
|
|
Friday, October 17, 2025 08:23 AM
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 31/10/25 | 2.28 | 2.40 | 2.24 | 2.37 | 478,100 |
| 30/10/25 | 2.34 | 2.37 | 2.25 | 2.26 | 449,800 |
| 29/10/25 | 2.30 | 2.42 | 2.22 | 2.37 | 1,631,900 |
| 28/10/25 | 2.41 | 2.44 | 2.28 | 2.30 | 409,900 |
| 27/10/25 | 2.43 | 2.45 | 2.32 | 2.38 | 740,900 |
| 24/10/25 | 2.32 | 2.41 | 2.25 | 2.36 | 740,700 |
| 23/10/25 | 2.25 | 2.33 | 2.21 | 2.31 | 460,100 |
| 22/10/25 | 2.13 | 2.27 | 2.10 | 2.27 | 594,100 |
| 21/10/25 | 2.14 | 2.16 | 2.02 | 2.14 | 573,700 |
| 20/10/25 | 1.87 | 2.15 | 1.82 | 2.14 | 1,454,700 |
|
|
||||
|
|
||||
|
|